MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Vela Technologies invests £2.35m in company developing Covid-19 treatment

StockMarketWire.com

Technology investor Vela Technologies said it had tipped £2.35 million into a company developing a potential Covid-19 treatment for diabetic patients.

Vela said it was funding the investment via a £1.25 million placing, at 0.1p per share.

It had acquired an economic interest in UK-based medical-charity St George Street Capital, which would pay Vela 8% of sale proceeds in excess of £19.2 million, after certain deductions.

St George Street was proposing to recruit up to 150 patients for a clinical trial to test the treatment SGS002, which it estimated would take five months to complete.

Vela said St George Street was working to a compressed timescale, given the urgency of the Covid-19 situation, and anticipated reaching clinical stage in early May 2021.

Separately, Vela also booked pre-tax losses for the six months through September of £63,000, compared to losses of £258,000 year-on-year.

At 9:07am: (LON:VELA) Vela Technologies share price was +0.01p at 0.08p


Story provided by StockMarketWire.com